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Abstract
Background: Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the
severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT),
whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and
phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and
the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-
term control add-on treatments, but they are restricted to the most severely affected patients because of safety
concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long
term despite long-term control having been acknowledged as one of the most important core outcome domains
to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the
disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.
(Continued on next page)
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Methods: This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one
winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard
care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin
D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat
measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes)
during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be
measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores,
serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT,
and synthetic patient-reported satisfaction at the end of each winter.
Discussion: This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D
supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term
control of disease activity. The experimental design enables the study of both interventions and exploration of the
interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term
control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic
dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially
effective low-cost therapeutic strategy for long-term control is essential for patients and public health.
Trial registration: ClinicalTrials.gov Identifier: NCT02537509, first received: 1 September 2015.
Keywords: Atopic dermatitis, vitamin D, phototherapy, long-term control, add-on therapy, pragmatic trial
Background
Atopic dermatitis (AD) is a common pruritic inflammatory
skin disease that classically has a chronic course of flares
and remissions. AD is a highly prevalent skin disorder, in
both adults (2–10%) [1–4] and children (15–20%) [1, 5–7],
and there is some evidence of an increase in AD prevalence
in some regions of the world, including Western Europe
[8]. Children with persistent and/or severe disease have in-
creased AD persistence in adulthood [9].
On the severity spectrum, lower-end patients benefit
from emollients and small amounts of topical cortico-
steroids, whereas higher-end patients need systemic
immunosuppressants; in-between patients are treated
with topical corticosteroids and tacrolimus (topical
anti-inflammatory treatments; TAT) and phototherapy.
The management of AD requires efficient control of
the flares. TAT are important anti-inflammatory drugs
used in AD flares. Topical corticosteroids applied on
inflammatory lesional skin are widely used as a
first-line treatment for disease flares. They have been
evaluated in a wide variety of preparations in more
than 110 different randomized controlled trials [10].
Topical calcineurin inhibitors are a second class of
TAT drugs that have also proved efficacious against
AD flares [11], and are administered alone or in com-
bination with topical steroids. Phototherapy is widely
used as a second-line treatment for the short-term
control of moderate-to-severe AD with demonstrated
efficacy, with intensive schedules of 2–7 sessions a
week for 2 or 3 months [12, 13].
These chronic in-between AD patients need large
amounts of TAT to maintain control of disease activity.
They certainly have the most markedly unmet medical
need, with a high impact on quality of life compared to
other chronic inflammatory skin diseases [14]. The
major therapeutic challenge in this population is the
long-term control (LTC) of disease activity, and the
current TAT-basedpro-active strategy (intermittent ap-
plications of TAT after flares on previously affected skin,
over long-term periods) does not meet all the needs.
There is also consistent evidence of subclinical inflam-
mation in skin of normal appearance and in the treated
skin of AD patients. Similarly, there is evidence that
treatments might improve this sub-clinical inflamma-
tion, prevent new flares or decrease the risk of new
flares in long-termfollow-up [15]. Current treatments for
LTC include strategies such as daily emollient applica-
tion, intermittent use of TAT (TAT-based strategy: once
or twice a week [15–18]), avoidance strategies, dietary
interventions, and immunosuppressive drugs.
‘Add-on’ therapies, which are superimposed on stand-
ard TAT, seem promising for LTC. Systemic immuno-
suppressants are used as LTC add-on treatments, but
they are reserved for the most severely affected patients
because of safety concerns. In addition, neither immuno-
suppressants nor other strategies (with the exception of
desensitization) [19] have been evaluated in the long
term. LTC is one of the most important core outcome
domains to be targeted in AD trials according to the
HOME (Harmonising Outcome Measures for Eczema)
Droitcourt et al. Trials          (2019) 20:184 Page 2 of 11
recommendations [20]. Safe add-on therapies, rigorously
evaluated for disease LTC, are therefore needed.
Phototherapy is a good candidate for the ‘in-between’
AD population, being widely used as a second-line treat-
ment in AD with demonstrated efficacy [12]. However,
only short-term control has been evaluated, and only in-
tensive schedules of two or three sessions per week have
been tested and are used in current practice. A novel
phototherapy regimen enabling a trade-off between dis-
ease control, ultraviolet (UV)-induced risks, and patient
acceptability is required for LTC of the disease. No ser-
ious short-term adverse events were collected in the re-
view by Garritsen et al. [12], where the most common
adverse event was xerosis.
Vitamin D supplementation is another good candidate
for the ‘in-between’ AD population, with several studies
having shown lower serum levels of vitamin D to be cor-
related with more severe AD [21–26]. However, in these
types of association studies, confounding factors such as
solar exposure and socio-economic level, can be a major
limitation. These observational studies are supported by
some evidence that vitamin D could play a role in the
different stages of AD pathogenesis [27, 28]. A
meta-analysis on trials testing vitamin D supplementa-
tion yielded conflicting results, leaving its therapeutic ef-
ficacy undecided for short-term control and unknown
for LTC [25].
We hypothesize that spaced-out phototherapy sessions
during winter (exploratory trial) and vitamin D as an
add-on therapy (main trial) could be beneficial to im-
prove LTC of disease activity among AD patients.
Methods/Design
Objectives
Since both phototherapy and vitamin D supplementation
are good candidates for LTC of disease activity in AD,
we propose to study these two treatments jointly for the
LTC of AD.
Trial design
The study is a pragmatic, multicenter, national, random-
ized (1:1), superiority, crossover (two periods, two se-
quences) trial lasting 2 years (including two successive
winters), and exploring add-on phototherapy versus ob-
servation in subjects receiving standard care (i.e., TAT).
In the same population, we will be testing the LTC pro-
vided by oral supplementation of vitamin D versus pla-
cebo in a randomized, superiority, double-blind,
parallel-group trial. Pragmatic trials [29] are the
best-suited designs for studying add-on therapies in the
context of long-term AD disease. The main pragmatic
options are the following: recruitment in a primary care
population, standard vitamin D supplementation,
regimen not adapted to serum levels, strictly ‘as usual’
TAT use, and no recommendation on changes in
lifestyle.
Study setting
The study will be conducted in 16 French hospital cen-
ters with a network of primary care dermatologists in
France.
Participants and eligibility criteria
Inclusion criteria
Eligibility criteria: patients with AD (Hanifin and Rajka cri-
teria), aged 15 or over, with > 2 years of disease evolution,
moderate-to-severe disease (Investigator Global Assess-
ment > 2), seasonality in disease severity (improvement in
summer), and fewer than 100 previous phototherapy ses-
sions in their lifetime. Eligible patients are to have received
TAT for at least 12 weeks and to have symptoms requiring
an intensification of the therapy, and they are to have easy
access to a phototherapy cabin (widely available in primary
care dermatology private practices in France).
Exclusion criteria
Exclusion criteria: patients with AD known to be aggra-
vated by UV exposure; indication for a systemic im-
munosuppressant in the next 2 years; any cause of
contra-indication for vitamin D supplementation: granu-
lomatosis flare, primary hyperparathyroidism; clinical
suspicion of hypercalciuria; any contra-indication for
artificial or solar photo-exposure including genetic dis-
ease predisposing to skin cancer, any history of skin can-
cer (melanoma, squamous and basal skin cancers),
lupus, dermatomyositis, any other photosensitizing skin
disease, photosensitizing medication; and more than 100
previous phototherapy sessions in their lifetime.
Interventions
– Oral vitamin D supplementation will be
administered at 100,000 IU, mono-dose (cholecalcif-
erol, UVEDOSE®), every 3 months (standard guide-
lines) for 2 years. UVEDOSE® is marketed by
NextPharma LIMAY. The placebo of oral vitamin D
supplementation is developed and marketed by
NextPharma LIMAY.
– Phototherapy: the NB-UVB regimen will include a
period of escalation of 3 weeks (three sessions per
week for 3 weeks) and after that every 2 weeks for 6
months in total (winter: October to March). For
phototype II–III, NB-UVB is initiated at 0.2 J/cm2
per session and is increased in increments of 0.1
from session to session up to the ninth session. For
maintenance (every 2 weeks), we will continue with
the dosage of the ninth session (1.0 or 1.1 J/cm2).
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The dosage can be altered according to clinical tol-
erance. For phototype IV–V, NB-UVB is initiated at
0.3 J/cm2 per session and is increased in increments
of 0.1 from session to session up to the ninth ses-
sion. For maintenance (every 2 weeks), we will main-
tain the exposure level of the ninth session (1.1 or
1.2 J/cm2). The exposure can be altered according to
clinical tolerance.
Outcomes
Primary outcomes
The primary outcomes are (1) repeat measures of the
Patient-Oriented Severity of Atopic Dermatitis Index
(PO-SCORAD) severity score over 1 year and (2) cumu-
late consumption of TAT (number of tubes) during the
winter; the outcomes will be tested following a hierarch-
ical testing procedure. The choice of a patient-related
score as the primary outcome will enable the capture of
more data points without increasing the number of
visits, and it is also coherent with the pragmatic design
of the study.
Secondary outcomes
The secondary outcomes are repeat measures over 2
years for investigator-based severity scores (Eczema Area
and Severity Index, Severity of Atopic Dermatitis Index,
Investigator Global Assessment); patient-reported sever-
ity and quality of life scores (Patient-Oriented Eczema
Measure, Dermatology Life Quality Index); serum vita-
min D levels (25-(OH)-vitamin D); total IgE serum
levels; weeks of satisfactory control; inter-visit cumulate
consumption of TAT; and synthetic patient-reported sat-
isfaction at the end of each winter.
Our trial includes all the recent core domains cited in
the HOME recommendations [20].
Recruitment
Particular attention will be given to recruiting a primary
care population. Each region is organized from a
university-based dermatology department into several
‘field study sites’ gathering several participating primary
care dermatologists.
Meetings will be organized with primary care derma-
tologists to invite them to participate and to inform
them on how the study will unfold. A trained study
nurse will help them check their patients’ eligibility and
plan the visits. The patients will have the possibility of
receiving their phototherapy with their primary care
dermatologist; scheduled visits will take place every 6
weeks.
Sample size
We used the General Linear Multivariate Model Power
& Sample Size (GLIMMPSE) software [30] to calculate
the sample size for a repeat measure analysis with a de-
sired power of at least 80%, a Type I error set at 0.05,
and equal group sizes. The main predictor variable is
phototherapy (yes or no) and the response variable is
numerical (PO-SCORAD). Repeat measures are de-
scribed as follows: 10 to 12 measures with time as the
unit, and an equal distance between repeat numerical
measures (every 4 weeks); we entered means for each
time according to an anticipated evolution over time,
and standard deviations of the response variable were
set at 18. GLIMMPSE currently assumes that the stand-
ard deviation is constant across repeat measures. As we
have some uncertainty about what standard deviation
value to use, we used alternative values for variability
and computed power for half the variance, the variance
as specified, and twice the variance; this was also applied
to means. GLIMMPSE automatically combines the
sources of correlation into a final covariance matrix
using a structured correlation based on the linear expo-
nential auto-regressive model. The model describes a
correlation that decreases monotonously with the dis-
tance between measures; the base correlation is set at
0.6 and the decay rate at 0.05. It can be noted that the
minimum clinically significant difference for the
PO-SCORAD score is indeed around 9, but we adopted
a stance enabling the detection of a smaller difference,
which means we are in an even better position to detect
a clinically relevant difference.
We considered a main effect hypothesis test for the ef-
fect of a single predictor variable averaged across all
other factors. We used the Hotelling–Lawley trace as
the recommended statistical test for this kind of design,
with a simple ‘between’ hypothesis and a complex
‘within’ hypothesis. We indeed plan to use a mixed
model for our data analysis, and we will use the Wald
test with Kenward–Roger degrees of freedom. It can be
noted that the Hotelling–Lawley trace test for the gen-
eral linear multivariate model coincides with the Wald
test for the general linear mixed model.
On the basis of the sample size simulation (Add-
itional file 1), we chose a total sample size of 340 sub-
jects. This calculation was performed on the basis of a
parallel-arm design; thus, using a crossover design, we
considered we could halve the sample size. The assump-
tion of no carry-over effect is allowed when planning a
sample size for a crossover trial. For an intervention only
in winter, we considered carryover would be minimized
by design. Using a uniform and balanced crossover de-
sign, the treatment difference will not be aliased with se-
quence or period effects. However, an interaction of
time and treatment should be taken into account, as we
anticipate this could occur.
Power considerations in the area of repeat measures,
crossover design and interaction between time and
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treatment are not straightforward. We therefore used
GLIMMPSE, as for a two-arm trial. We realize that halv-
ing the sample size could appear simplistic and we
therefore compared the sample size calculations between
(1) a two parallel arm trial and (2) a crossover trial, con-
sidering only the last measure as the outcome, to check
that the sample size reduction was not too optimistic. Fi-
nally, anticipating that 10–15% of patients will not
complete the entire study (two 1-year sequences), the
planned number of subjects to be enrolled is set at 200.
Participant timeline
Following the opening of screening in January, patients
can enter the study at any time; they will go through a
pre-screening period until they are randomized in Sep-
tember. We have chosen a common fixed period for in-
clusion to avoid confounding seasonality factors. During
the pre-screening period, trial outcomes are collected
but no treatment is given. Enrollment is preceded by a
pre-screening period of 9 months to identify patients
with inclusion criteria, and exclude, before
randomization, any participants who are unlikely to be
adherent. A patient will be in the trial for 2 years
post-randomization (i.e., until September 2019 for those
entering in September 2017). After the inclusion visit,
visits will occur every 3 months over 2 years. Further-
more, each patient will complete the self-administered
questionnaires including the PO-SCORAD at home
through an application on their computer or phone, or
otherwise on paper, every 4 weeks. The time schedule of
enrolment and visits is provided in Table 1 and Fig. 1.
Assignment of interventions
Sequence generation and allocation concealment
mechanism
Participants who meet the eligibility criteria and have
signed informed consent will then be randomly assigned,
in a 1:1 ratio, to either vitamin D or placebo, and within
each arm to either the sequence UV–observation or the
sequence observation–UV through an automated
web-based system. A permuted block randomization
scheme will be used, with stratification according to the
clinical site, age (three age groups) and disease severity
(two groups: moderate or severe). The list will be bal-
anced by blocks of random size in order to ensure total
unpredictability. Randomization can occur on the day of
inclusion (Visit 1).
Since we offer phototherapy sessions exclusively dur-
ing winter periods, the carry-over effect is not a concern
in our study (Fig. 2).
Blinding
This study is conducted as open-label regarding photo-
therapy, since blinding cannot be implemented, but it is
double-blind for vitamin D therapy.
Vitamin D: patients, investigators and outcome asses-
sors will be blinded. Although it would have been pos-
sible to implement logistics with a blinded switch to
Table 1 Time schedule of enrolment and visits
Actions Visit 0 Screening Visit 1 Inclusion Visits 2–8
Follow-up
Visit 9
End of trial
Written informed consent X
Web-based randomization X
Demographic details X X
Medical history X X X X
Physical examination X X X X
Investigator Global Assessment X X X X
Eczema Area and Severity Index, Severity of Atopic
Dermatitis Index
X X X
Quality of Life: Dermatology Life Quality Index X X X
Patient-Oriented Severity of Atopic Dermatitis Index,
Patient-Oriented Eczema Measure
X X Computer record every 4 weeks X
Estimation of solar exposure X X X
Complete blood count, serum chemistry, serum
creatinine, serum
calcium and phosphate, serum parathyroid level
X X
Serum total IgE level X X X
Vitamin D dosage X X X
Delivery of oral vitamin D or placebo vial X X
Checking for adverse events X X
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Fig. 1 Overview of the study
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placebo for patients reaching normal vitamin D levels, the
absence of supplementation dose adaptation based on
vitamin D serum level will help maintain the blinding.
Phototherapy: patients and investigators will not be
blinded, and cannot be. We will address the problem of
blinding with regard to phototherapy by masking the al-
located treatment (phototherapy or observation) for the
investigator in charge of scoring disease severity. How-
ever, some objective clues (e.g., tanning, if present) can-
not be masked.
Data collection, management, and analysis
Data collection methods
Table 1 shows data collection at inclusion and at follow-
up visits.
Data management
All information required by the study protocol is to be
recorded in the case report forms and an explanation is
to be provided for any missing data. Data is to be col-
lected progressively, as obtained, and recorded explicitly
in the case report forms.
An electronic case report form (e-CRF) will be made
available and data capture will be carried out in the cen-
ters using a web interface (Clinsight software, Ennov,
Paris, France). Only an Internet connection and a
browser are required. A document on how to use this
tool will be provided for the investigators. The interface
between the clinical research associate and the investiga-
tor will thus be provided, also making remote data col-
lection and control possible. Data consistency tests will
be incorporated in electronic format. An audit function
is incorporated in the e-CRF, thus making it possible to
follow any change in study data. This function also
makes it possible to clearly identify the person who has
made a change, with the date; comments can be added.
If requested, a hard copy will be printed at the end of
the study, authenticated (dated and signed) by the inves-
tigator, and copies will be sent to the sponsor and
archived.
The procedures applied are those used Rennes CHU
and comply with Good Clinical Practice and the legal
and regulatory requirements in force.
Statistical methods
The statistical issue for the primary outcomes is the ana-
lysis of repeat measures (up to 12 measures for each
1-year period, on the PO-SCORAD, a self-administered
questionnaire the results of which are collected through
an application on computer or phone, at home) applied
to a crossover design (two 1-year periods, two se-
quences). When repeat measures are analyzed, there are
many possible hypotheses that could be of interest. We
focused on a main effect hypothesis test for the effect of
a single predictor variable (treatment: phototherapy) av-
eraged across all other factors, and the sample size cal-
culation was designed accordingly. We are interested in
the usual factors, namely ‘Treatment’ (phototherapy/no
phototherapy) and ‘Time’. However, the nature of the
design (crossover trial) needs to be taken into account.
This means that we need to consider the following fac-
tors: ‘Period’ – first winter/second winter, ‘Order’ –
phototherapy–no phototherapy or no phototherapy–
phototherapy, and ‘Carry-over’. It was anticipated that
vitamin D could act as a quantitative effect-modifier on
phototherapy. We therefore decided to include an inter-
action term in the analysis. We will use a single model
with the following main effects: Treatment-1 (photother-
apy/no phototherapy), and Treatment-2 (vitamin D/
Fig. 2 Figure SPIRIT
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placebo), Period, Order, and Carry-over terms as well as
an interaction term between Treatment-2 and
Treatment-1. As an interaction of Time and Treatment
could occur, we plan to add an interaction term to the
model. The other primary outcome, the cumulate con-
sumption of TAT (number of tubes) during the winter, is
a quantitative variable. It will be analyzed using a mixed
model with the following main effects: Treatment-1
(phototherapy/no phototherapy), and Treatment-2 (vita-
min D/placebo), Period, Order, and Carry-over terms as
well as an interaction term between Treatment-2 and
Treatment-1. As this outcome is a summary of winter
consumption, no interaction of Time and Treatment will
be added to this model. Adjustment will be made on the
variables used in the allocation process (region – north
vs. south), age as a continuous variable, and disease se-
verity (moderate vs. severe).
For descriptive purposes, it is instructive to carry out
an analysis based on a summary of the statistics (a quan-
tity calculated from each curve), which can reflect im-
portant aspects of the problem at hand – we have
chosen the area under the curve (AUC) and the mean
amplitude of PO-SCORAD score ranges. Descriptive sta-
tistics (mean and standard deviation) of the
PO-SCORAD for each visit will also be provided. Nor-
mal distribution is assumed in the modeling analysis for
the primary outcomes (PO-SCORAD severity score over
two 1-year periods; cumulate consumption of TAT dur-
ing winter) and will be checked at this stage.
The main analysis will be based on the adjusted model
and will follow the ‘intention to treat’ principle, namely
all participants, as randomized, will be analyzed; out-
come data obtained from all participants, regardless of
protocol adherence, will be used. Mixed model tech-
niques (PROC MIXED) will be applied.
The multiplicity adjustment strategy used is a hier-
archical closed test procedure, where the primary end-
points are ordered as follows: (E1) repeat measures of
the PO-SCORAD severity score over 1 year and (E2) cu-
mulate consumption of TAT over winter. We will test
E1 and E2 sequentially at the same two-sided level of
0.05; we will test E1 first, if it proves significant, will we
test E2. A Wald test with Kenward–Roger degrees of
freedom will be used.
No subgroup analyses nor interim analyses are planned.
For secondary analyses, we will use up to four mea-
sures per 1-year period, collected at each clinical visit
(every 3 months), including investigator-based severity
scores (Eczema Area and Severity Index, Severity of
Atopic Dermatitis Index, Investigator Global Assess-
ment), patient-reported severity and quality of life scores
(Patient-Oriented Eczema Measure, Dermatology Life
Quality Index), serum vitamin D levels, total IgE serum
levels, weeks of satisfactory control, inter-visit cumulate
consumption of TAT, and synthetic patient-reported sat-
isfaction at the end of each winter.
All analyses will use procedures available in SAS soft-
ware 9.4 (SAS Institute, Carry, NC, USA).
Methods: Monitoring
Data monitoring
A clinical research technician will be responsible for co-
ordinating the study; specifically, the logistics and moni-
toring of the study, the production of reports on
progress, verifying that the e-CRFs are updated, dispatch
of blood samples, and notification severe adverse events
(AEs) to the sponsor. The technician will follow the
Standardized Operating Procedures. The data monitor-
ing technician will be dependent towards the sponsor
and independent from the study investigators. Investiga-
tors will make the data available to the persons in charge
of monitoring, quality checks, or audit of the study doc-
uments, and they will provide individual data that is
strictly necessary for such checking, in compliance with
the legislative and regulatory conditions in force (articles
L.1121–3 and R.5121–13 in the French public health
code).
Adverse events
Any serious AEs, whether or not related to the medical
object under study, expected or unexpected, must be re-
ported within 24 h by the investigator to the sponsor on a
“Serious AE” form, on which should be specified the date
of occurrence, the severity rating, the intensity, the rela-
tionship with the treatment evaluated (or the study), and
the outcome. All other AEs will be reported on the “AE”
form in the case report form specifying the date of occur-
rence, the description, the severity, the duration, the
method of resolution, the causal relationship, and the de-
cisions made. The sponsor will report all suspected unex-
pected serious adverse drug reactions to Eudravigilance
(the European pharmacovigilance database), the French
Health Products Agency (Agence de Sécurité du Médic-
ament et des Produits de Santé), and the investigators,
within the regulatory time periods for reporting.
Auditing
The investigators agree to undergo quality assurance au-
dits conducted by the sponsor as well as inspections per-
formed by the competent authorities. All data and all
documents and reports can be subjected to audits and
regulatory inspections without limitation in relation to
medical confidentiality.
Ethics and dissemination
Ethics approval for the research
The sponsor and the investigators undertake to conduct
this study in compliance with French law no. 2004–806
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of August 9, 2004, and with Good Clinical Practice and
the Helsinki Declaration (Ethical Principles for Medical
Research involving Human Subjects, Tokyo, 2004). The
study will be conducted in accordance with this proto-
col. Excluding emergency situations requiring specific
therapeutic actions, the investigators will observe the
protocol in all respects, particularly regarding consent
and the notification and follow-up of serious AEs.
The protocol was approved on 18/08/15 by the
“Comité de protection des Personnes” and received
authorization from the French Health Products Agency
on 27/07/15.
Consent
Patients will be completely and openly informed, in
terms that are understandable to them, of the objectives
and constraints of the study, of the possible risks in-
curred, of the required measures of supervision and
safety, of their right to refuse to participate in the study,
and of the possibility of withdrawing their consent at
any time.
All this information is contained in an information
and consent form given to the patient. The patients’ free,
informed and written consent will be collected by the in-
vestigator, or a doctor representing them prior to final
inclusion in the study. A copy of the information and
consent form signed by both parties will be given to the
patient; the investigator will keep the original.
Confidentiality and access to data
In compliance with the conditions of confidentiality of
data to which individuals in charge of quality control of
biomedical studies have access (article L.1121–3 in the
French public health code), and with conditions pertain-
ing to confidentiality of information, in particular con-
cerning the type of investigational medical design, the
tests, subjects in the study, and the results obtained (art-
icle R. 5121–13 in the French public health code), indi-
viduals having direct access will take all necessary
precautions to ensure confidentiality of the information.
Dissemination policy
The data provided by the investigating centers will be
analyzed by INSERM CIC 1414 Rennes. A written report
on the results will be submitted to the sponsor and pub-
lished on ClinicalTrials.gov.
Scientific presentations and reports corresponding to
the study will be drafted under the responsibility of the
coordinating investigator of the study with the agree-
ment of the investigators in charge. Rules for publication
will follow international recommendations [31]. In ac-
cordance with law no. 2002–303 of March 4, 2002, pa-
tients will be informed, at their request, of the overall
results of the study.
SPIRIT guidelines
This protocol has been written in accordance with the
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) guidelines. The SPIRIT check-
list is provided in Additional file 2.
Discussion
AD is a highly prevalent disease in both adults and chil-
dren, with acknowledged unmet needs, in particular in
the LTC of the disease, which has not been widely evalu-
ated in published studies. Novel and safe therapeutic
strategies are needed for long-term AD control and a
potentially effective low-cost therapeutic strategy for
LTC is essential for patients and public health.
The international, multi-professional initiative HOME
aims to standardize and validate AD outcome measure-
ments. LTC has been defined as a core domain to be
assessed in AD studies, but the corresponding outcome
measure has not yet been established and future re-
search is needed [20]. The HOME initiative encourages
the conduct of trials on LTC of AD, and cites two broad
approaches to explore LTC; the first is the assessment of
weeks during which the disease is well-controlled and
the second is to perform serial measurements of the
other three core domains (signs, symptoms, and quality
of life). HOME has validated a duration of more than 3
months for future AD trials assessing LTC. Because TAT
cannot be entirely withdrawn, testing ‘add-on’ therapies
for LTC of AD needs both the collection of AD severity
measures and an evaluation of TAT consumption. In this
trial, our proposal is to evaluate AD severity by serial
measurements of investigator- and patient-reported se-
verity scores over a 2-year period, alongside TAT
consumption.
Since both phototherapy and vitamin D supplementa-
tion are good candidates for LTC of AD disease activity,
our proposal is to study these two treatments jointly.
We will therefore use a factorial design to assess the ef-
fects of phototherapy and vitamin D supplementation on
LTC within the same study; since solar exposure (and to
a lesser extent artificial UV exposure under photother-
apy) favors vitamin D synthesis, this design has the po-
tential to explore the interaction between phototherapy
and vitamin D supplementation in disease control and
serum vitamin D levels in winter and all-year round. We
have chosen a crossover design for phototherapy to ad-
just on personal characteristics (phototherapy and sensi-
tivity to UV exposure being major determinants of
phototherapy efficacy) [32–34]. We chose a fixed and
common period for inclusion to avoid confounding by
seasonality. While patients will be able to sign their writ-
ten consent at any time in the pre-screening period, they
will be randomized in September and we cannot exclude
that some patients may drop out of the study before the
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randomization. The alternative would be to randomize
patients throughout the year and to take into account
seasonal effects, but the approach to measure this would
have been complex in a study with pragmatic options
and long-termfollow-up. Since we provide phototherapy
sessions exclusively during winter periods, a carry-over
effect is not a concern in our study.
Our trial provides the possibility of reducing topical
antiinflammatory treatment use. Further evaluation will
be needed if the exploratory trial on phototherapy opens
up new avenues (novel phototherapy, pro-active strategy).
As we are conducting a long-term study, we plan the
following procedures to minimize attrition bias: firstly,
any participant who is recommended systemic immuno-
suppressants will discontinue the study; secondly, our
trial includes strong pragmatic options [29, 34–36] such
as primary care population, standard vitamin D supple-
mentation that is not adapted to serum levels, ‘as usual’
TAT use, and no recommendations for changes in life-
style; thirdly, the trial includes logistic support to ensure
adherence such as trained study nurses in the field facili-
tating participant adherence; and, finally, it will test new
maintenance therapies superimposed on usual care. It
can be noted that ‘add-on’ therapy trials on asthma have
better rates of adherence [37].
Trial status
The protocol is currently recruiting in 16 French cen-
ters. The first patient was included on September 30,
2015, and recruitment is anticipated to end in Septem-
ber 2020.
Additional files
Additional file 1: Details on sample size calculation. (DOCX 75 kb)
Additional file 2: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 98 kb)
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